Verkazia™ (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick

by Business Wire • 2021/06/30 • 0 Comments

TORONTO--(BUSINESS WIRE)--Verkazia Reimbursement for New Brunswick

← Face Mask Detects SARS-CoV-2

Q&A: AAPA seeks ‘physician associate’ title change despite opposition from AMA →